SHEL.UK

2,875

-0.09%↓

SHEL.UK

2,875

-0.09%↓

SHEL.UK

2,875

-0.09%↓

SHEL.UK

2,875

-0.09%↓

SHEL.UK

2,875

-0.09%↓

Search

Smith & Nephew PLC

Fermé

1,321 0.19

Résumé

Variation du prix de l'action

24h

Actuel

Min

1309.5

Max

1332.5

Chiffres clés

By Trading Economics

Revenu

296M

Ventes

3B

P/E

Moyenne du Secteur

31.207

25.238

BPA

0.429

Rendement du dividende

2.99

Marge bénéficiaire

9.895

Employés

17,000

EBITDA

723M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+12.5% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

2.99%

4.00%

Prochains Résultats

2 mars 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

11B

Ouverture précédente

1320.81

Clôture précédente

1321

Smith & Nephew PLC Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

15 févr. 2026, 23:21 UTC

Acquisitions, Fusions, Rachats

Qube Agrees to Takeover by MAM-Led Consortium Valuing Its Equity at $6.51 Billion

15 févr. 2026, 23:45 UTC

Market Talk

Nikkei May Rise as Fears About AI Disruption Recede -- Market Talk

15 févr. 2026, 23:40 UTC

Market Talk

Gold Falls on Possible Position Adjustments -- Market Talk

15 févr. 2026, 23:06 UTC

Résultats

Thai Beverage: Spirits, Beer Businesses Posted Satisfactory EBITDA Growth, Alongside Profit Margin Expansion>Y92.SG

15 févr. 2026, 23:04 UTC

Résultats

Thai Beverage 1Q Beer Business EBITDA THB4.64B, Up 4.7% on Year>Y92.SG

15 févr. 2026, 23:04 UTC

Résultats

Thai Beverage 1Q Spirits Business EBITDA THB8.50B, Up 6.9% on Year >Y92.SG

15 févr. 2026, 23:01 UTC

Résultats

Thai Beverage 1Q EBITDA THB16.75B, Up 1.8% on Year >Y92.SG

15 févr. 2026, 23:01 UTC

Résultats

Thai Beverage 1Q FY Sales Revenue THB86.70B, Down 6.0% on Year>Y92.SG

15 févr. 2026, 22:53 UTC

Acquisitions, Fusions, Rachats

Qube: MAM-Led Offer Implies A$11.7 Billion Enterprise Value

15 févr. 2026, 22:53 UTC

Acquisitions, Fusions, Rachats

Qube: UniSuper to Transfer 15.07% Stake to Equivalent Ownership of Consortium Holding Structure

15 févr. 2026, 22:52 UTC

Acquisitions, Fusions, Rachats

Qube Shareholders to Receive A$5.20/Share in Cash

15 févr. 2026, 22:52 UTC

Acquisitions, Fusions, Rachats

Qube Holdings Agrees to Takeover by Macquarie Asset Management-Led Consortium

15 févr. 2026, 22:22 UTC

Acquisitions, Fusions, Rachats

BlueScope CEO Tania Archibald Speaking on a Call With Media

15 févr. 2026, 22:17 UTC

Acquisitions, Fusions, Rachats

BlueScope CEO: Stresses Whyalla Project Would Have to Make Sense to Shareholders

15 févr. 2026, 22:16 UTC

Acquisitions, Fusions, Rachats

BlueScope CEO: Some Job Cuts Inevitable to Ensure Company is Competitive

15 févr. 2026, 22:14 UTC

Acquisitions, Fusions, Rachats

BlueScope CEO: Higher Returns Tied to End of Capital Investment Program

15 févr. 2026, 22:14 UTC

Acquisitions, Fusions, Rachats

BlueScope Steel CEO: Higher Returns After Rebuffed Takeover Bid a 'Natural Coincidence'

15 févr. 2026, 20:48 UTC

Résultats

BlueScope: Will Now Target Net Debt of Up to A$1.5 Billion; Will Surpass as Needed

15 févr. 2026, 20:47 UTC

Résultats

BlueScope: Expects Full Benefits of Further A$150M Cost Savings in FY 2027

15 févr. 2026, 20:46 UTC

Résultats

BlueScope: Recorded Net Annualized Cost Improvements of A$190 Million in 1H

15 févr. 2026, 20:45 UTC

Résultats

BlueScope Expects a One-Third Lower 2H Result From Asia Business Vs 1H

15 févr. 2026, 20:44 UTC

Résultats

BlueScope Expects 15% Higher 2H Result From North America Business Vs 1H

15 févr. 2026, 20:44 UTC

Résultats

BlueScope Expects Lower 2H Result From Australia Business Vs 1H

15 févr. 2026, 20:43 UTC

Résultats

BlueScope Expects 2H Underlying Ebit of A$620 Million-A$700 Million

15 févr. 2026, 20:42 UTC

Résultats

BlueScope Net Debt A$2.2 Million at Dec. 31

15 févr. 2026, 20:42 UTC

Résultats

BlueScope 1H Underlying Ebit A$557.5 Million, Up 81% On-Year

15 févr. 2026, 20:41 UTC

Résultats

BlueScope 1H Underlying Ebitda A$915.3 Million, Up 39% On-Year

15 févr. 2026, 20:40 UTC

Résultats

BlueScope 1H Underlying Profit A$382.0 Million Vs A$176.4 Million Year Prior

15 févr. 2026, 20:40 UTC

Résultats

BlueScope 1H Sales Revenue From Continuing Ops A$8.22 Billion, Up 4% On-Year

15 févr. 2026, 20:39 UTC

Résultats

BlueScope Intends to Spend A$310 Million on Buyback, Or Other Returns if Share Repurchases Limited

Comparaison

Variation de prix

Smith & Nephew PLC prévision

Objectif de Prix

By TipRanks

12.5% hausse

Prévisions sur 12 Mois

Moyen 1,490.57 GBX  12.5%

Haut 1,650 GBX

Bas 1,290 GBX

Basé sur 7 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

7 ratings

5

Achat

2

Maintien

0

Vente

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Smith & Nephew PLC

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
help-icon Live chat